Trial Profile
A Multicenter, Randomized, Double-blind Phase III Trial to Evaluate Efficacy and Safety of BI 695502 Plus Chemotherapy Versus Avastin Plus Chemotherapy in Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Antineoplastics; Carboplatin; Paclitaxel
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms INVICTAN-2
- Sponsors Boehringer Ingelheim
- 26 May 2019 Trial has been completed in Croatia.
- 22 Nov 2018 Status changed from active, no longer recruiting to completed.
- 19 Nov 2018 Planned End Date changed from 30 Mar 2019 to 18 Nov 2018.